-
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
-
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
-
Protagenic completes first dose in PT00114 multiple-dose phase 1 trial
-
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
-
Protagenic Therapeutics receives Japan patent for epilepsy drug compounds
-
Protagenic Therapeutics Inc. (PTIX) Receives $3.1 Million from Recent Warrant Activity
-
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
-
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Protagenic Therapeutics, Inc. Merger
-
Protagenic Therapeutics (PTIX) and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company
-
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic
-
Protagenic Therapeutics Inc. (PTIX) Announces 1:14 Reverse Share Split
-
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
-
Protagenic Therapeutics Inc. (PTIX) Files for 5.84M Share Offering by Selling Stockholders
-
Protagenic Therapeutics (PTIX) Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
-
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
-
Protagenic Therapeutics Inc. (PTIX) Prices 1.95M Share Private Placement at $0.64/sh
-
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
-
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

